A federal appeals court said the patent office made legal errors in awarding foundational patents for CRISPR-Cas9 to the ...

The University of California and the University of Vienna on Monday convinced a U.S. appeals court to revive their bid for ...

A favorable appeals court ruling repositioned a coalition of universities and Nobel laureates to win credit for inventing a ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

The CRISPR-led gene-editing revolution is set to begin next month in its first ever trial in humans ... than current PD-1–targeted drugs as the technology directly knocks-out the gene ...

The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 gene-editing technology in humans to directly correct the genetic mutation that causes the disease. Sickle cell disease is a genetic ...

The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 gene-editing technology in humans to directly correct the genetic mutation that causes the disease. The research involves taking ...